Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VIVS with free AI briefings, catalyst countdowns, and dilution alerts.

VIVS · VivoSim Labs, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.6M Cash on Hand
9mo Cash Runway
Follow VIVS by email Get an email when VIVS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VIVS, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

VIVS holds $8.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.8M/quarter from operations, an estimated runway of 9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VIVS files for a raise →

👥 Who Owns VIVS

Insiders 0.8% Other 5%+ holders 1.6% Institutions (26 holders) 11.1% Public and other holders 86.5%
HolderTypeShares% of sharesAs of
Esousa Group Holdings LLC 5%+ holder (13G) 319,429 1.57% 2026-06-30
Vaidehi Joshi
Director
Insider 58,821 0.29% 2024-08-07
Keith Murphy
EXECUTIVE CHAIRMAN, Director · +143,731 options
Insider 26,053 0.13% 2026-01-27
Douglas Jay Cohen
Director
Insider 20,898 0.10% 2026-01-27
Adam K Stern
Director
Insider 19,899 0.10% 2026-01-27
Alison Tjosvold Milhous
Director
Insider 19,899 0.10% 2026-01-27
David Gobel
Director
Insider 15,000 0.07% 2026-01-27
Tony Serge Lialin
Chief Commercial Officer · +40,000 options
Insider 10,000 0.05% 2026-08-31

Share count 20,281,495 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VIVS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VIVS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.